Ardelyx(ARDX) - 2024 Q4 - Annual Results

Financial Performance - Unaudited U.S. net product sales revenue of IBSRELA (tenapanor) for Q4 2024 was approximately $54 million, and approximately$158 million for the full year 2024[8] - Unaudited U.S. net product sales revenue of XPHOZAH (tenapanor) for Q4 2024 was approximately $57 million, and approximately$161 million for the full year 2024[8] - As of December 31, 2024, the company had cash, cash equivalents, and short-term investments of approximately $250 million[3] Financial Data Disclosure - The preliminary financial data is subject to adjustment and may differ materially in the audited financial statements[4] - The preliminary financial data is the responsibility of the company's management and has not been audited or reviewed by Ernst & Young LLP[5]